It remains to be seen whether the company can turn itself around after settling issues with the US Department of Justice even as it managed to narrow its net loss in the June quarter
Ranbaxy Laboratories Ltd said its net loss during the first quarter narrowed to Rs608.8 crore on depreciation of Indian rupee and change in accounting standards.
For the quarter to end-June, the drug maker, a unit of Japanese Daiichi Sankyo Co Ltd said its net loss narrowed to Rs608.9 crore from Rs925.7 crore while its total revenues, including sales, declined to Rs1469.9 crore from Rs1587 crore, same period last year.
Arun Sawhney, chief executive and managing director of Ranbaxy, said, “We successfully concluded the previously disclosed investigation by the US Department of Justice (DOJ). With the payment of $500 million provisioned earlier, we have settled both the civil and criminal settlements with the DOJ. This should allow us to focus our resources and energies to drive future growth.”
During the quarter, the drug maker’s revenues from API business increased 31% to Rs226.3 crore driven by focus on select markets and product mix. During the quarter, the company filed one ANDA was filed for the US market.
Sales in north America, during the June quarter, was Rs851.6 million, lower than last year, due to expiry of select exclusivities. However, it has a strong sales base in Absorica. The company says that its market share gain in Absorica, isotretenonin NDA has been promising and it holds a share of 13.7%, overall.
Some key highlights of Ranbaxy products are:
The exclusivity period for Pioglitazone hydrochloride authorised generic came to an end in mid-February 2013 and the company holds a market share of 24%;
Ranbaxy has 43% market share in Cevimeline hydrochloride 30 milligrams capsules in the US market.
Ranbaxy closed Wednesday 4.6% up at Rs281.9 on the BSE, while the 30-share Sensex ended the day marginally down at 18664.9.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
